Atlas Trials

Medy-Tox

49 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Medy-Tox

RecordFirmDate
Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat (NCT05195112)Medy-Tox2021-12-24
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) (NCT04157686)Medy-Tox2019-10-23
Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX® (NCT04281745)Medy-Tox2019-10-17
A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat (NCT04144049)Medy-Tox2019-09-10
Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder (NCT04113941)Medy-Tox2019-08-23
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines (NCT04143854)Medy-Tox2019-05-21
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines (NCT04143815)Medy-Tox2019-05-20
Observational Study to Determine the Efficacy and Safety of Potenfill for Temporary Penile Enhancement (NCT04496427)Medy-Tox2019-04-10
MT10109L in the Treatment of Glabellar Lines (NCT03795922)Medy-Tox2018-12-24
MT10109L in the Treatment of Lateral Canthal Lines (NCT03785145)Medy-Tox2018-12-20
The Efficacy and Safety of Repeat-dose Potenfill for Temporary Penile Enhancement (NCT03840070)Medy-Tox2018-12-17
The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines (NCT03837561)Medy-Tox2018-12-13
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines (NCT03732833)Medy-Tox2018-11-05
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL) (NCT03721016)Medy-Tox2018-10-26
Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject (NCT03759743)Medy-Tox2018-09-04
Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis (NCT03760198)Medy-Tox2018-08-03
Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects (NCT03905291)Medy-Tox2018-07-31
Neuramis® Volume Lidocaine for Volume Augmentation in the Mid-Face (NCT03754413)Medy-Tox2018-05-29
Pharmacodynamic and Safety of MBA-P01 in Healthy Male Volunteers (NCT03547141)Medy-Tox2018-04-16
MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy (NCT03452345)Medy-Tox2018-04-09
Neuramis® Deep Lidocaine Compared to YVOIRE® Volume Plus for Correction of Nasolabial Folds (NCT03753152)Medy-Tox2018-04-02
Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Valunteers (NCT03647982)Medy-Tox2018-03-20
Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder (NCT03371342)Medy-Tox2017-12-13
Efficacy and Safety of Potenfill for Temporary Penile Enhancement (NCT03512717)Medy-Tox2017-11-16
CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3) (NCT03289702)Medy-Tox2017-11-13

Track Medy-Tox automatically

Every clearance here is in the API, with alerts when new ones post.